Zolgensma, the gene therapy, developed and marketed by the pharmaceutical company Novartis, won both FDA approval and the title of "world's most expensive drug" earlier this year. However, it's recently come to light that Novartis knowingly provided the FDA manipulated data during the approval process. Dr. Chris Gerry explains what went wrong, why this is such a big deal, and whether Zolgensma should stay on the market.
A newly-approved Novartis drug combination showed impressive efficacy in reducing cardiac death and morbidity from congestive heart failure, one of the most common ailments taking the lives and health of America s senior population.
Meningococcal disease is a bacterial infection that can lead to serious complications such as hearing loss, brain or kidney damage, limb amputations and possibly death. Although there are antibiotics that may reduce risk of